Humana Inc. (NYSE:HUM)‘s stock had its “outperform” rating restated by stock analysts at Cowen and Company in a note issued to investors on Wednesday. They presently have a $275.00 target price on the insurance provider’s stock, up from their prior target price of $230.00. Cowen and Company’s price objective would indicate a potential upside of 14.56% from the stock’s current price.

A number of other equities analysts have also recently commented on HUM. UBS AG reaffirmed a “neutral” rating and set a $237.00 price objective (up from $205.00) on shares of Humana in a research report on Wednesday, June 28th. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Morgan Stanley lifted their target price on Humana from $269.00 to $276.00 and gave the stock an “overweight” rating in a report on Thursday, August 17th. Zacks Investment Research downgraded Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $223.00 target price (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $246.60.

Shares of Humana (NYSE:HUM) traded down 0.87% during trading on Wednesday, hitting $237.96. 943,285 shares of the stock were exchanged. The firm’s 50-day moving average is $250.95 and its 200 day moving average is $232.23. The company has a market cap of $34.39 billion, a P/E ratio of 19.58 and a beta of 0.87. Humana has a 1-year low of $163.50 and a 1-year high of $259.76.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same period in the previous year, the business posted $2.30 earnings per share. Equities analysts forecast that Humana will post $11.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/20/humanas-hum-outperform-rating-reiterated-at-cowen-and-company.html.

In other Humana news, insider Elizabeth D. Bierbower sold 9,786 shares of Humana stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the transaction, the insider now owns 18,042 shares in the company, valued at $4,672,878. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Timothy S. Huval sold 7,803 shares of Humana stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the transaction, the vice president now owns 8,831 shares in the company, valued at approximately $2,279,634.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,566 shares of company stock worth $15,326,746. Company insiders own 0.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in HUM. WFG Advisors LP grew its position in Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares during the last quarter. Guardian Life Insurance Co. of America grew its position in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 4 shares during the last quarter. Acrospire Investment Management LLC bought a new position in Humana in the second quarter valued at about $120,000. Independent Portfolio Consultants Inc. grew its position in Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after acquiring an additional 94 shares during the last quarter. Finally, Point72 Asia Hong Kong Ltd bought a new position in Humana in the first quarter valued at about $128,000. Hedge funds and other institutional investors own 95.12% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.